New IPF drug interaction study completed in healthy volunteers
NCT ID NCT07588646
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how a new drug called HEC585 interacts with two existing medicines for idiopathic pulmonary fibrosis (IPF): pirfenidone and nintedanib. Thirty-three healthy adults took part to measure drug levels and safety. The goal was to see if combining these drugs causes any changes in how they work in the body.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Xuhui Central Hospital
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- What makes someone stop a lung fibrosis drug? a study asks patients directly
- A smarter way to track lung disease? new platform aims to personalize COPD and IPF care
- AI outruns radiologists in detecting early lung scarring
- Experimental drug aims to slow lung scarring in IPF
- AI-Designed drug targets scarred lungs in major trial
- Can scans replace breathing tests to monitor lung scarring?